CRTX
Price:
$1.95
Market Cap:
$78.66M
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Industry
Biotechnology
IPO Date
2019-05-09
Stock Exchange
NASDAQ
Ticker
CRTX
According to Cortexyme, Inc.’s latest financial reports and current stock price. The company's current ROE is -172.68%. This represents a change of 257.01% compared to the average of -48.37% of the last 4 quarters.
The mean historical ROE of Cortexyme, Inc. over the last ten years is -48.21%. The current -172.68% ROE has changed 258.18% with respect to the historical average. Over the past ten years (40 quarters), CRTX's ROE was at its highest in in the March 2018 quarter at 108.87%. The ROE was at its lowest in in the March 2025 quarter at -80.89%.
Average
-48.21%
Median
-40.75%
Minimum
-188.51%
Maximum
60.33%
Discovering the peaks and valleys of Cortexyme, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 411.04%
Maximum Annual ROE = 60.33%
Minimum Annual Increase = -128.95%
Minimum Annual ROE = -188.51%
Year | ROE | Change |
---|---|---|
2024 | -188.51% | 411.04% |
2023 | -36.89% | -28.17% |
2022 | -51.36% | -31.82% |
2021 | -75.33% | 68.85% |
2020 | -44.61% | 40.02% |
2019 | -31.86% | 82.39% |
2018 | -17.47% | -128.95% |
The current ROE of Cortexyme, Inc. (CRTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-92.25%
5-year avg
-79.34%
10-year avg
-48.21%
Cortexyme, Inc.’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cortexyme, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cortexyme, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Cortexyme, Inc.'s ROE?
How is the ROE calculated for Cortexyme, Inc. (CRTX)?
What is the highest ROE for Cortexyme, Inc. (CRTX)?
What is the 3-year average ROE for Cortexyme, Inc. (CRTX)?
What is the 5-year average ROE for Cortexyme, Inc. (CRTX)?
How does the current ROE for Cortexyme, Inc. (CRTX) compare to its historical average?